TLRY · Tilray Brands, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on TLRY. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About TLRY · Tilray Brands, Inc.
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Live Quote
SELL (score -5) · 12-1 mom 43.7% · RSI 31.6 · below_both · -78.0% from high
Targets blend Wall Street consensus (9 analysts: low $6.50 / mean $10.04 / high $24.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Tilray is a multi-segment lifestyle consumer goods company anchored by medical/recreational cannabis but increasingly reliant on craft beverage assets (BrewDog, SweetWater, Breckenridge) following years of acquisitions. The June 9, 2026 8-K reveals a debt-for-equity exchange that reduced the convertible note burden by ~$6M while diluting shareholders — consistent with ongoing balance sheet management rather than strategic inflection. The company has executed a 1-for-10 reverse stock split (Dec 2, 2025) and is burning cash on an operating basis (-$52.7% margin). Revenue declined 7.8% YoY to $858M TTM. The stock is 77% below its 52-week high of $23.20 and trades far below all moving averages (MA200: $9.44). Cannabis rescheduling remains a theoretical catalyst but has failed to move the needle over many years — and the company's heavy Canada/EU revenue exposure limits direct U.S. legalization benefit. No insider open-market purchases in 90 days, only RSU vesting and one director sale. The options market shows elevated IV (0.98-1.00 for near-term ATM puts) but no whale positioning. Given persistent unprofitability, revenue decline, heavy dilution history, and a catalyst that has repeatedly failed to materialize, there is no compelling asymmetric setup here — either direction.
{"symbol":"TLRY","company":"Tilray Brands, Inc.","investigation_summary":"Tilray is a small-cap cannabis-and-beverage conglomerate that has collapsed ~76% from its October 2025 high of $23.20 to $5.55 following a 1-for-10 reverse split and sustained revenue decline (-7.8% YoY). The company posted an EPS beat in May 2025 (+$0.20 vs. flat estimate) but then badly missed Q3 FY2026 (Feb) at -$0.02 vs.
Recent news from TradeBytes mentioning TLRY
Articles from the sister news site that name this ticker. Independent of the AI pipeline's research.